AstraZeneca files Crestor/TriLipix combination
This article was originally published in Scrip
AstraZeneca and Abbott have filed a US NDA for Certriad, a combination of AstraZeneca's Crestor (rosuvastatin calcium) and Abbott's TriLipix (fenofibric acid), for the treatment of mixed dyslipidaemia. The two firms have also entered into a co-promotion agreement for TriLipix, further strengthening the ties between them in the cardiovascular area – they already have an agreement whereby Abbott co-promotes Crestor in the US.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.